Abstract：
OBJECTIVE: To determine the indications for radiotherapy in salivary gland cancer and to specify the modalities and target radiation volumes.
METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
RESULTS: Postoperatively, radiotherapy to the primary tumor site±to the lymph nodes is indicated if one or more of the following adverse histoprognostic factors are present (risk>10% of locoregional recurrence): T3-T4 category, lymph node invasion, extraglandular invasion, close or positive surgical margins, high tumor grade, perineural invasion, vascular emboli, and/or bone invasion. Intensity-modulated radiation therapy (IMRT) is the gold standard. For unresectable cancers or inoperable patients, carbon ion hadrontherapy may be considered.
CONCLUSIONS: Radiotherapy in salivary gland cancer is indicated in postoperative situations in case of adverse histoprognostic factors and for inoperable tumors.
METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
RESULTS: Postoperatively, radiotherapy to the primary tumor site±to the lymph nodes is indicated if one or more of the following adverse histoprognostic factors are present (risk>10% of locoregional recurrence): T3-T4 category, lymph node invasion, extraglandular invasion, close or positive surgical margins, high tumor grade, perineural invasion, vascular emboli, and/or bone invasion. Intensity-modulated radiation therapy (IMRT) is the gold standard. For unresectable cancers or inoperable patients, carbon ion hadrontherapy may be considered.
CONCLUSIONS: Radiotherapy in salivary gland cancer is indicated in postoperative situations in case of adverse histoprognostic factors and for inoperable tumors.
摘要：
目的：确定唾液腺癌放射治疗的适应症，并指定方式和目标放射量。
方法：法国罕见头颈部肿瘤网络（REFCOR）成立了一个指导小组，该小组对Medline上发表的文献进行了叙述性综述，并提出了建议。然后由评级小组评估对建议的遵守程度，根据正式共识方法。
结果：术后，如果存在以下一种或多种不良组织预后因素（局部复发的风险>10％），则表明对原发肿瘤部位±淋巴结进行放射治疗：T3-T4类别，淋巴结浸润，外来入侵，手术切缘接近或阳性，肿瘤分级高,神经周浸润,血管栓塞,和/或骨侵入。调强放射治疗(IMRT)是金标准。对于无法切除的癌症或无法手术的患者，碳离子强子疗法可以考虑。
结论：唾液腺癌的放疗适用于不良组织预后因素和不能手术的肿瘤的术后情况。
方法：法国罕见头颈部肿瘤网络（REFCOR）成立了一个指导小组，该小组对Medline上发表的文献进行了叙述性综述，并提出了建议。然后由评级小组评估对建议的遵守程度，根据正式共识方法。
结果：术后，如果存在以下一种或多种不良组织预后因素（局部复发的风险>10％），则表明对原发肿瘤部位±淋巴结进行放射治疗：T3-T4类别，淋巴结浸润，外来入侵，手术切缘接近或阳性，肿瘤分级高,神经周浸润,血管栓塞,和/或骨侵入。调强放射治疗(IMRT)是金标准。对于无法切除的癌症或无法手术的患者，碳离子强子疗法可以考虑。
结论：唾液腺癌的放疗适用于不良组织预后因素和不能手术的肿瘤的术后情况。
